title: Attenuation of lipopolysaccharide anorexia by antagonism of caudal brain stem but not forebrain GLP-1-R.
abstract: The central glucagon-like peptide-1 (GLP-1) system has been implicated in the control of feeding behavior. Here we explore GLP-1 mediation of the anorexic response to administration of systemic LPS and address the relative importance of caudal brain stem and forebrain GLP-1 receptor (GLP-1-R) for the mediation of the response. Fourth-intracerebroventricular delivery of the GLP-1-R antagonist exendin-(9-39) (10 microg) did not itself affect food intake in the 24 h after injection but significantly attenuated the otherwise robust (approximately 60%) reduction in food intake obtained after LPS (100 microg/kg) treatment. This result highlights a role for caudal brain stem GLP-1-R in the mediation of LPS anorexia but does not rule out the possibility that forebrain receptors also contribute to the response. Forebrain contribution was addressed by delivery of the GLP-1-R antagonist to the third ventricle with the caudal flow of cerebrospinal fluid blocked by occlusion of the cerebral aqueduct. Exendin-(9-39) delivery thus limited to forebrain did not attenuate the anorexic response to LPS. These data suggest that LPS anorexia is mediated, in part, by release of the native peptide acting on GLP-1-R within the caudal brain stem.
authors.affiliation: Graduate Groups of Psychology and Neuroscience, University of Pennsylvania, Philadelphia, PA 19104, USA. grill@psych.upenn.edu
authors.forename: Harvey J
authors.initials: HJ
authors.lastname: Grill
authors.forename: Jill S
authors.initials: JS
authors.lastname: Carmody
authors.forename: L
authors.initials: L
authors.lastname: Amanda Sadacca
authors.forename: Diana L
authors.initials: DL
authors.lastname: Williams
authors.forename: Joel M
authors.initials: JM
authors.lastname: Kaplan
mesh_terms: D000818:Animals; D000855:Anorexia / Q000139:chemically induced / Q000517:prevention & control*; D001933:Brain Stem / Q000187:drug effects / Q000502:physiology*; D002535:Cerebral Aqueduct / Q000502:physiology; D000067757:Glucagon-Like Peptide-1 Receptor; D006185:Habituation, Psychophysiologic / Q000502:physiology; D007276:Injections, Intraventricular; D008070:Lipopolysaccharides / Q000037:antagonists & inhibitors* / Q000494:pharmacology*; D008297:Male; D010446:Peptide Fragments / Q000494:pharmacology; D016548:Prosencephalon / Q000187:drug effects / Q000502:physiology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D018027:Receptors, Glucagon / Q000037:antagonists & inhibitors*; D020542:Third Ventricle / Q000502:physiology
chemical_list: C000593835:Glp1r protein, rat; D000067757:Glucagon-Like Peptide-1 Receptor; D008070:Lipopolysaccharides; D010446:Peptide Fragments; D018027:Receptors, Glucagon; C083773:exendin (9-39)